Recro Enters Into Master Commercial Supply and Services Agreement With Otsuka Agreement Establishes Recro as Commercial Supplier for Otsuka Deal Validates Recro’s “Second Source” Strategy of Supporting Commercial Programs as U.S.-Based Supplier GAINESVILLE, Ga. and SAN...

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan –  Esperion to Receive $60 Million Upfront Payment  – –  Up to $510 Million in Total Milestones  – –  Substantial Tiered Royalties  – –  Combines Esperion’s Expertise in Lipid Management with...

Otsuka Pharmaceutical Development & Commercialization, Inc. Develops Relapse Risk Assessment For Schizophrenia Patients (RASP): A New Self-Report Screening Tool Gettysburg, PA, May 09, 2018 (GLOBE NEWSWIRE) -- Nearly 3.4 million adults, or 1.1% of the U.S. population, are affected by schizophrenia.1,2 As a chronic, relapsing condition, those who have...

2017 OPEN MINDS Technology & Informatics Faculty List Announced; Includes Leaders From Over 30 Influential Health & Human Service Organizations Gettysburg, PA, Oct. 17, 2017 (GLOBE NEWSWIRE) -- OPEN MINDS recently announced the faculty list for this year’s 2017 OPEN MINDS Technology & Informatics Institute taking place on November 7-8,...

Cutting Edge Information Analyzes the Bristol-Myers Squibb / Otsuka Pharma Profit-Sharing Strategy for 2010 and Beyond RESEARCH TRIANGLE PARK, NC--(Marketwire - April 16, 2009) - The recently announced deal between Bristol-Myers Squibb and Otsuka over Abilify will go a long way toward shoring up both companies'...